CEL-SCI Corp CVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
-
CEL-SCI Reports Fiscal Third Quarter 2026 Results
-
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
-
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
-
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
Trading Information
- Previous Close Price
- $2.42
- Day Range
- $2.29–2.83
- 52-Week Range
- $0.89–10.62
- Bid/Ask
- $2.80 / $2.88
- Shares Outstanding
- 17.59M
- Market Cap
- $48.19M
- Volume/Avg
- 45 / 249,635
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.cel-sci.com
Valuation
|
Metric
|
CVM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CVM
|
|---|---|
Quick Ratio | 1.29 |
Current Ratio | 1.48 |
Interest Coverage | −50.13 |
Quick Ratio
CVM
Profitability
|
Metric
|
CVM
|
|---|---|
Return on Assets (Normalized) | −91.46% |
Return on Equity (Normalized) | −194.44% |
Return on Invested Capital (Normalized) | −102.04% |
Return on Assets
CVM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#^#B#% | LOCK|??N$ | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|HDg@q?j | LOCK|L@?@ | $76B | |||
| Moderna Inc
MRNA
| LOCK|r>R$!? | LOCK|<^w | $75B | |||
| argenx SE ADR
ARGX
| LOCK|$XH%?S | LOCK|@# | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#ks&YvB | LOCK|kv? | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@lXk@&& | LOCK|r?k% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<#^P&>^F | LOCK|S?Nyk | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|wDngZ@ | LOCK|@#& | $24B | |||
| Incyte Corp
INCY
| LOCK|>m$!^<& | LOCK|<B% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|z@dHsb | LOCK|&&? | $15B |
United States